PORTLAND, Ore.--(BUSINESS WIRE)--April 12, 2005-- Presentations Include Ebola, Influenza, Dengue, SARS Coronavirus and Bunyavirus Studies at the International Conference on Antiviral Research AVI BioPharma, Inc. (Nasdaq:AVII), today announced the release of extensive data in five presentations on its NEUGENE(R) antisense approach to developing antiviral therapeutics. The presentations will be given at the 18th International Conference on Antiviral Research, in Barcelona, Spain, being held April 10-14. Two studies have been selected for plenary oral presentations. The first presentation, titled “Development of a Phosphorodiamidate Morpholino Oligomer Antisense to Ebola Zaire,” highlights experiments performed in the laboratory of Sina Bavari, Ph.D., at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The study is part of AVI’s ongoing research in biodefense with the Chemical and Biological Defense Program of the Office of the Secretary of Defense. The presentation will be given by Patrick L. Iversen, Ph.D., senior vice president of research and development of AVI.
